We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...

The Hatch-Waxman Act has always represented a delicate balance between the interests of innovator and generic drugmakers: innovators seek to maintain exclusivity as broadly and long as possible, ...

Highmark recently shared how it increased generic and biosimilar access to members, focusing on drugs for multiple sclerosis, cancer and autoimmune conditions. The insurer has been working with ...

In 2026, Novo Nordisk’s patent on semaglutide will expire in several countries, including India and China. Generic-drug makers are poised to flood these markets with inexpensive products. Industry ...

Cuban said the high fees the FDA charges to approve generic drugs are a major barrier to manufacturing lower-priced generics in the United States, according to the report. Cuban said Cost Plus Drugs, ...

Cuban urges FDA fee waiver to boost US generics manufacturing Cost Plus Drugs plans to boost US production if fees are waived FDA charges $360,000 per generic drug approval application Trump promised ...

Copyright: © 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies. A similar scenario is now ...

U.S. District Judge Cynthia Rufe, of the Eastern District of Pennsylvania, gave the claims recovery firms seven days to provide lead counsel with a list of names and contact information for all class ...

A terminal-based university course registration system built in Java, applying robust OOP principles and supporting roles like Students, Professors, Admins, and Teaching Assistants. Includes GPA ...

The US Food and Drug Administration will take steps to streamline the development of generic versions of complex biological drugs, the agency announced Wednesday. The changes are meant to accelerate ...

CEO Narasimhan says no tariff impact on guidance Top-selling heart drug Entresto sees growth stall Older drugs hit by 'generic erosion' in US market Newer drugs help offset some of the slowdown ...

FRANKFURT (Reuters) -Swiss drugmaker Novartis met third-quarter profit forecasts on Tuesday, as fast growth of newer drugs offset a sharp slowdown in blockbuster heart drug Entresto as it comes under ...